search button

Measurement of mid-arm muscle circumference and prognosis in stage IV non-small cell lung cancer patients

  • Authors:
    • Rafaela Festugatto Tartari
    • Jane Maria Ulbrich‑Kulczynski
    • Antônio Fabiano Ferreira Filho

  • View Affiliations

  • Published online on: January 11, 2013     https://doi.org/10.3892/ol.2013.1128
  • Pages: 1063-1067
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Overall survival (OS) varies widely in patients with stage IV non-small cell lung cancer (NSCLC). Strong prognostic factors are still needed to improve decision-making regarding standard treatment options, to stratify patients for inclusion in innovative therapeutic trials and to identify patients who would be best treated with palliative care rather than with systemic chemotherapy. Mid-arm muscle circumference (MAMC) is a bedside anthropometric measurement that estimates somatic protein reserve, an early indicator of nutritional depletion. This measurement is simple, non‑invasive, objective and inexpensive to perform. We evaluated MAMC as a potential prognostic factor in patients with stage IV NSCLC. A total of 56 non-selected consecutive patients with stage IV NSCLC were evaluated. The MAMC measurement results for these patients were expressed as a percentage of the expected reference values, adjusted for gender and age. Patients were categorized as normal (MAMC ≥90%) or depleted (MAMC <90%). The mean age of patients was 63 years (range 47-80), and the mean MAMC was 89 (range 66-122), with 55% of patients classified as depleted. The median OS was 6.2 months (95% CI, 5.1-7.3). In the subgroup with normal MAMC, the median OS was 10.2 months (95% CI, 9.2-11.1). In patients classified as depleted, the median OS was 5.0 months (95% CI, 4.2-5.8). The difference in OS between these two subgroups was highly significant (p<0.001 by the log-rank test; HR=0.21; 95% CI, 0.09-0.5 for patients with normal MAMC). In a multivariate analysis with Karnofsky status, age and gender as covariates, the difference in OS between the MAMC groups remained statistically significant (p<0.001, according to the Cox proportional hazards model). MAMC is a strong independent prognostic factor in stage IV NSCLC patients. Patients with MAMC <90% of the expected value had poor OS.
View Figures
View References

Related Articles

Journal Cover

March 2013
Volume 5 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Tartari RF, Ulbrich‑Kulczynski JM and Ferreira Filho AF: Measurement of mid-arm muscle circumference and prognosis in stage IV non-small cell lung cancer patients. Oncol Lett 5: 1063-1067, 2013
APA
Tartari, R.F., Ulbrich‑Kulczynski, J.M., & Ferreira Filho, A.F. (2013). Measurement of mid-arm muscle circumference and prognosis in stage IV non-small cell lung cancer patients. Oncology Letters, 5, 1063-1067. https://doi.org/10.3892/ol.2013.1128
MLA
Tartari, R. F., Ulbrich‑Kulczynski, J. M., Ferreira Filho, A. F."Measurement of mid-arm muscle circumference and prognosis in stage IV non-small cell lung cancer patients". Oncology Letters 5.3 (2013): 1063-1067.
Chicago
Tartari, R. F., Ulbrich‑Kulczynski, J. M., Ferreira Filho, A. F."Measurement of mid-arm muscle circumference and prognosis in stage IV non-small cell lung cancer patients". Oncology Letters 5, no. 3 (2013): 1063-1067. https://doi.org/10.3892/ol.2013.1128